Immunoproteasomal Processing of IsoLG-Adducted Proteins Is Essential for Hypertension
CONCLUSIONS: These studies define a previously unknown role of the immunoproteasome in DCs and ECs in CD8+ T cell activation. The immunoproteasome in DCs and ECs is critical for isoLG-adduct presentation to CD8+ T cells, and in the endothelium, this guides homing and infiltration of T cells to specific tissues.PMID:38623763 | DOI:10.1161/CIRCRESAHA.124.324068 (Source: Circulation Research)
Source: Circulation Research - April 16, 2024 Category: Cardiology Authors: N éstor de la Visitación Wei Chen Jaya Krishnan Justin P Van Beusecum Venkataraman Amarnath Elizabeth M Hennen Shilin Zhao Mohammad Saleem Mingfang Ao Sergey I Dikalov Anna E Dikalova David G Harrison David M Patrick Source Type: research
Immunoproteasomal Processing of IsoLG-Adducted Proteins Is Essential for Hypertension
CONCLUSIONS: These studies define a previously unknown role of the immunoproteasome in DCs and ECs in CD8+ T cell activation. The immunoproteasome in DCs and ECs is critical for isoLG-adduct presentation to CD8+ T cells, and in the endothelium, this guides homing and infiltration of T cells to specific tissues.PMID:38623763 | DOI:10.1161/CIRCRESAHA.124.324068 (Source: Circulation Research)
Source: Circulation Research - April 16, 2024 Category: Cardiology Authors: N éstor de la Visitación Wei Chen Jaya Krishnan Justin P Van Beusecum Venkataraman Amarnath Elizabeth M Hennen Shilin Zhao Mohammad Saleem Mingfang Ao Sergey I Dikalov Anna E Dikalova David G Harrison David M Patrick Source Type: research
MiR-34c-5p Inhibition Affects Bax/Bcl2 Expression and Reverses Bortezomib Resistance in Multiple Myeloma Cells
This study aimed to determine the expression profile of XBP1, hsa-miR-34c-5p, hsa-miR-214, and hsa-miR-30c-2* in resistant and sensitive multiple myeloma cell lines to a proteasome inhibitor, bortezomib. After establishing bortezomib-resistant cells, the expression level of XBP1, hsa-miR-214, hsa-miR-34c-5p, and hsa-miR-30c-2* in both cell lines were assessed by qRT-PCR. Hsa-miR-34c-5p was suppressed to study its effect on the expression profile of Bax/Bcl-2. Statistical analysis was done by t-test in two clinically resistant and sensitive cells to bortezomib. MTT assay confirmed the creation of the resistant cell line. Th...
Source: Indian Journal of Hematology and Blood Transfusion - April 11, 2024 Category: Hematology Source Type: research
Proteasome ‐dependent degradation of histone H1 subtypes is mediated by its C‐terminal domain
AbstractHistone H1 is involved in chromatin compaction and dynamics. In human cells, the H1 complement is formed by different amounts of somatic H1 subtypes, H1.0-H1.5 and H1X. The amount of each variant depends on the cell type, the cell cycle phase, and the time of development and can be altered in disease. However, the mechanisms regulating H1 protein levels have not been described. We have analyzed the contribution of the proteasome to the degradation of H1 subtypes in human cells using two different inhibitors: MG132 and bortezomib. H1 subtypes accumulate upon treatment with both drugs, indicating that the proteasome ...
Source: Protein Science - April 9, 2024 Category: Biochemistry Authors: D. Garc ía‐Gomis,
J. López,
A. Calderón,
M. Andrés,
I. Ponte,
A. Roque Tags: RESEARCH ARTICLE Source Type: research
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures
Leukemia, Published online: 09 April 2024; doi:10.1038/s41375-024-02243-5Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures (Source: Leukemia)
Source: Leukemia - April 9, 2024 Category: Hematology Authors: Saurabh Zanwar Morie A. Gertz Eli Muchtar Francis K. Buadi Taxiarchis Kourelis Wilson Gonsalves Ronald S. Go Suzanne Hayman Prashant Kapoor Moritz Binder Joselle Cook David Dingli Nelson Leung Yi Lin Rahma Warsame Amie Fonder Miriam Hobbs Yi Lisa Hwa Robe Source Type: research
Cancers, Vol. 16, Pages 1448: Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial
erzah M. Horton
Steven M. Kornblau
The addition of the proteasome inhibitor bortezomib to standard chemotherapy did not improve survival in pediatric acute myeloid leukemia (AML) when all patients were analyzed as a group in the Children’s Oncology Group phase 3 trial AAML1031 (NCT01371981). Proteasome inhibition influences the chromatin landscape and proteostasis, and we hypothesized that baseline proteomic analysis of histone- and chromatin-modifying enzymes (HMEs) would identify AML subgroups that benefitted from bortezomib addition. A proteomic profile of 483 patients treated with AAML1031 chemother...
Source: Cancers - April 9, 2024 Category: Cancer & Oncology Authors: Anneke D. van Dijk Fieke W. Hoff Yihua Qiu Stefan E. Hubner Robin L. Go Vivian R. Ruvolo Amanda R. Leonti Robert B. Gerbing Alan S. Gamis Richard Aplenc Edward A. Kolb Todd A. Alonzo Soheil Meshinchi Eveline S. J. M. de Bont Terzah M. Horton Steven M. Kor Tags: Article Source Type: research
Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors
Bioorg Med Chem. 2024 Mar 16;104:117680. doi: 10.1016/j.bmc.2024.117680. Online ahead of print.ABSTRACTMany disease states require multiple drugs to inhibit multiple targets for their effective treatment/management, i.e. a drug cocktail regimen, or "polypharmacy". Polypharmacology, in contrast, is the development of single agents that can inhibit multiple targets. Each strategy is associated with advantages and disadvantages. Motivated by promising clinical trial data for the treatment of multiple myeloma with the combination of the HDAC6 inhibitor ricolinostat and the proteasome inhibitor bortezomib, we herein describe a ...
Source: Bioorganic and Medicinal Chemistry - April 6, 2024 Category: Chemistry Authors: Alexandria M Chan Ashley Mitchell Lena Grogan Paul Shapiro Steven Fletcher Source Type: research
Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors
Bioorg Med Chem. 2024 Mar 16;104:117680. doi: 10.1016/j.bmc.2024.117680. Online ahead of print.ABSTRACTMany disease states require multiple drugs to inhibit multiple targets for their effective treatment/management, i.e. a drug cocktail regimen, or "polypharmacy". Polypharmacology, in contrast, is the development of single agents that can inhibit multiple targets. Each strategy is associated with advantages and disadvantages. Motivated by promising clinical trial data for the treatment of multiple myeloma with the combination of the HDAC6 inhibitor ricolinostat and the proteasome inhibitor bortezomib, we herein describe a ...
Source: Bioorganic and Medicinal Chemistry - April 6, 2024 Category: Chemistry Authors: Alexandria M Chan Ashley Mitchell Lena Grogan Paul Shapiro Steven Fletcher Source Type: research
B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer
Sci Rep. 2024 Apr 2;14(1):7733. doi: 10.1038/s41598-024-58424-w.ABSTRACTB-Myb has received considerable attention for its critical tumorigenic function of supporting DNA repair. However, its modulatory effects on chemotherapy and immunotherapy have rarely been reported in colorectal cancer. Bortezomib (BTZ) is a novel compound with chemotherapeutic and immunotherapeutic effects, but it fails to work in colorectal cancer with high B-Myb expression. The present study was designed to investigate whether B-Myb deletion in colorectal cancer could potentiate the immune efficacy of BTZ against colorectal cancer and to clarify the...
Source: Cancer Control - April 2, 2024 Category: Cancer & Oncology Authors: Yuan-Jian Hui Ting-Ting Yu Liu-Gen Li Xing-Chun Peng Mao-Jun Di Hui Liu Wen-Long Gu Tong-Fei Li Kai-Liang Zhao Wei-Xing Wang Source Type: research
Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients
CONCLUSIONS: Polymorphism in CYP2C19 enzyme is likely to have an impact on bortezomib treatment response and peripheral neuropathy. The study suggests the role of pharmacogenetics in personalised treatment of MM.PMID:38561047 | DOI:10.1016/j.amjms.2024.03.022 (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - April 1, 2024 Category: General Medicine Authors: Lavisha Goel Pooja Gupta Lalit Kumar Thirumurthy Velpandian Archana Singh Kalpana Luthra Yogendra Kumar Gupta Source Type: research
Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients
CONCLUSIONS: Polymorphism in CYP2C19 enzyme is likely to have an impact on bortezomib treatment response and peripheral neuropathy. The study suggests the role of pharmacogenetics in personalised treatment of MM.PMID:38561047 | DOI:10.1016/j.amjms.2024.03.022 (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - April 1, 2024 Category: General Medicine Authors: Lavisha Goel Pooja Gupta Lalit Kumar Thirumurthy Velpandian Archana Singh Kalpana Luthra Yogendra Kumar Gupta Source Type: research
Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients
CONCLUSIONS: Polymorphism in CYP2C19 enzyme is likely to have an impact on bortezomib treatment response and peripheral neuropathy. The study suggests the role of pharmacogenetics in personalised treatment of MM.PMID:38561047 | DOI:10.1016/j.amjms.2024.03.022 (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - April 1, 2024 Category: General Medicine Authors: Lavisha Goel Pooja Gupta Lalit Kumar Thirumurthy Velpandian Archana Singh Kalpana Luthra Yogendra Kumar Gupta Source Type: research
Heart and Lung Transplant in a Patient with Relapsed AL Amyloidosis
Introduction: AL amyloidosis is a systemic disease of abnormal light chain production and pathologic amyloid fibrils that infiltrate tissue and lead to organ dysfunction. Solid organ transplantation historically has played a small role in management due to concerns of multi-organ involvement and risk of relapse. Standard of care previously included cyclophosphamide, bortezomib, and dexamethasone (CyBorD). For relapsed disease, treatment options often included immunomodulatory drugs that are associated with an increased risk of transplant rejection or autologous bone marrow transplant. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Urey, E. Adler, V. Pretorius, M. Kearns, E. Golts, A. Kao, G. Yung, A. Kafi, C. Lin, C. Costello, K. Afshar Source Type: research
Myelomatous pleural effusion in multiple myeloma- A rare presentation
J Cancer Res Ther. 2024 Jan 1;20(1):476-478. doi: 10.4103/jcrt.jcrt_1772_22. Epub 2023 May 2.ABSTRACTMultiple myeloma is a malignant plasma cell condition that mostly affects the skeletal system and bone marrow. Pleural effusions are uncommon and typically result from other conditions coexisting with multiple myeloma. Malignant myelomatous pleural effusions are rare complications of multiple myeloma, occurring in less than 1% of patients and are associated with poor prognosis having mean survival of less than 4 months. The present case report is a 41-year-old multiple myeloma patient who developed bilateral pleural effusio...
Source: Cell Research - March 30, 2024 Category: Cytology Authors: Ingale Yaminy Pradeep R Kulkarni Mayuri S Patil Sourabh M Patel Nirali Source Type: research
Refractory guillain-barr É syndrome in a patient with asymptomatic multiple myeloma successfully treated with low-dose rituximab
Acta Clin Croat. 2023 Aug;62(2):382-386. doi: 10.20471/acc.2023.62.02.19.ABSTRACTDespite being extremely rare, Guillain-Barré syndrome (GBS) has been recognized as a neurological complication of multiple myeloma, with variable responses to plasmapheresis (PEX), intravenous immunoglobulins (IVIG), and anti-myeloma therapies. In this paper, we report a case of a female patient with asymptomatic multiple myeloma (aMM) who initially presented as PEX- and IVIG-refractory GBS. After failure of PEX, IVIG, and anti-myeloma therapy (bortezomib, melphalan, and prednisone), the patient was eventually successfully treated with low-do...
Source: Acta Clinica Croatica - March 29, 2024 Category: General Medicine Authors: Ivan Kre čak Velka Gveri ć-Krečak Source Type: research
